Combination of Atezolizumab & Pirfenidone in Second-line & Beyond NSCLC

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05543330` - A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC	Phase 1/Phase 2
Recruiting	`NCT04106180` - SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC	Phase 2
Recruiting	`NCT05215548` - Primary Tumor Resection With EGFR TKI for Stage IV NSCLC	Phase 2
Recruiting	`NCT04042558` - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	Phase 2
Completed	`NCT04507217` - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC	Phase 2
Recruiting	`NCT04467801` - Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy	Phase 2
Active, not recruiting	`NCT04027647` - Phase 2 Study of Dacomitinib in NSCLC	Phase 2
Recruiting	`NCT04768491` - Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Not yet recruiting	`NCT04492969` - Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
Recruiting	`NCT04116918` - Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
Terminated	`NCT03411473` - Study of AGEN1884 With Pembrolizumab in 1L NSCLC	Phase 2
Recruiting	`NCT03564197` - 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC	N/A
Not yet recruiting	`NCT06219317` - Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC	Phase 2
Not yet recruiting	`NCT04604470` - Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
Recruiting	`NCT05132218` - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Not yet recruiting	`NCT04136535` - Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC	Phase 2
Completed	`NCT03184571` - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	Phase 2
Completed	`NCT06339554` - Alectinib-induced Endocrine Toxicity
Active, not recruiting	`NCT04549428` - Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC	Phase 2
Recruiting	`NCT03647956` - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors	Phase 2

NCT number	NCT04467723
Study type	Interventional
Source	University of Kansas Medical Center
Contact	KUCC Navigator
Phone	9135883671
Email	KUCC_Navigation@kumc.edu
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	May 18, 2022
Completion date	August 2025

Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms